CD40 and B-cell non-Hodgkin lymphoma: Similarly, in hematological cancer (B cell NHL), CD40 engagement via dacetuzumab (humanised agonistic CD40 IgG1 mAb; alias: SGN-40) was tolerated well amongst patients.